Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP was upgraded by investment analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Friday.

Other analysts have also issued research reports about the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $10.00.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH traded down $0.02 during trading hours on Friday, reaching $8.32. 2,228,163 shares of the company traded hands, compared to its average volume of 1,609,360. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $1.19 billion, a PE ratio of -24.47 and a beta of 1.45. Aurinia Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $10.05. The stock has a fifty day simple moving average of $7.13 and a 200 day simple moving average of $6.11.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.08. The business had revenue of $67.77 million for the quarter, compared to analyst estimates of $59.07 million. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. As a group, research analysts predict that Aurinia Pharmaceuticals will post 0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of large investors have recently modified their holdings of AUPH. BNP Paribas Financial Markets raised its holdings in shares of Aurinia Pharmaceuticals by 12.0% in the 1st quarter. BNP Paribas Financial Markets now owns 78,466 shares of the biotechnology company's stock worth $393,000 after purchasing an additional 8,398 shares during the period. Nordea Investment Management AB raised its holdings in shares of Aurinia Pharmaceuticals by 51.7% during the 1st quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company's stock valued at $1,552,000 after buying an additional 105,100 shares during the period. ProShare Advisors LLC raised its holdings in shares of Aurinia Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company's stock valued at $173,000 after buying an additional 2,873 shares during the period. Jupiter Asset Management Ltd. raised its holdings in shares of Aurinia Pharmaceuticals by 21.3% during the 1st quarter. Jupiter Asset Management Ltd. now owns 247,052 shares of the biotechnology company's stock valued at $1,238,000 after buying an additional 43,366 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company's stock valued at $7,673,000 after buying an additional 21,119 shares during the period. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.